

TRINITY MOTHER FRANCES HOSPITALS AND CLINICS - TYLER, TEXAS
 INPATIENT ANTIBIOGRAM % SUSCEPTIBLE

DATE RANGE: JANUARY 2013 TO DECEMBER 2013

All organisms for which there are at least 30 isolates are included.

Aerobic Organisms Gram POSITIVE	Range of Isolates	Cefotaxime Meningitis	Cefotaxime Nonmeningitis	Ceftriaxone Meningitis	Ceftriaxone Nonmeningitis	Chloramphenicol	Clindamycin	Erythromycin	Levofloxacin	Linezolid	Penicillin G	Penicillin (parenteral) Meningitis	Penicillin (parenteral) Nonmeningitis	Penicillin (oral)	Nitrofurantoin (a)	Oxacillin	Rifampin	Tetracycline	Trimeth/sulfa	Vancomycin
	#	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Staph aureus	691-759	-	-	-	-	-	72(b)	36	-	-	11	-	-	-	100	51	-	95	99	100
MRSA* only	326-353	-	-	-	-	-	63(b)	11	-	100(c)	0	-	-	-	100	0	98	94	98	100
Coag neg Staph	498-612	-	-	-	-	-	59(b)	34	-	-	12	-	-	-	99	48	-	78	67	100
Enterococcus species	342-525	-	-	-	-	-	-	-	50(a)	100(d)	79	-	-	-	88	-	-	21	-	82(f)
Strep pneumoniae	70	77(e)	96(e)	80(e)	97(e)	97	88	63	100	-	-	41(e)	99(e)	33(e)	-	-	-	-	72	100

FIRST ISOLATE METHOD: For the purpose of guiding clinical decisions about empiric therapy of initial infections, only the first isolate of a given species per patient, per admission, irrespective of body site, antimicrobial susceptibility profile, or other phenotypic characteristics is included in data.

* Includes both community and hospital associated isolates.

Aerobic Organisms Gram NEGATIVE	Range of Isolates	Amikacin	Amox/Clav	Ampicillin	Amp/Sulbactam	Aztreonam	Ceftazidime	Cefazolin	Cefepime	Ceftriaxone	Cefuroxime	Ciprofloxacin	Gentamicin	Imipenem	Meropenem	Levofloxacin	Nitrofurantoin (a)	Pip/Tazo	Tetracycline	Tobramycin	Trimeth/sulfa
	#	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Escherichia coli (g)	391-1318	99	91	44	66	94	95	90	95	94	94	67	88	100	100	67	97	97	70	97	63
Enterobacter cloacae complex	73-88	100	-	-	-	89	-	0	97	89	-	93	94	-	96	-	-	84	-	98	86
Klebsiella pneumoniae (g)	71-379	99	99	0	87	94	88	92	96	94	90	95	98	100	99	95	58	96	84	99	90
Proteus mirabilis	33-177	100	-	54	77	89	93	79	93	92	88	64	80	-	99	64	0	100	3	90	60
Pseudomonas aeruginosa	37-264	98	-	-	-	95	-	95	-	-	-	85	96	90	95	85	-	87	-	97	-
Serratia marcescens	31-39	100	-	-	-	100	-	0	100	100	-	85	95	-	97	-	-	-	-	85	87

(a) Nitrofurantoin is only reported on urine isolates.

(b) Tested for Inducible Clindamycin Resistance (D Test)

(c) Tested only on MRSA, Respiratory isolates (90 isolates)

(d) Tested only on VRE (93 isolates)

(e) S. pneumoniae: Breakpoints differ for Cefotaxime, Ceftriaxone, and Penicillin based on diagnosis.

(f) 93 VRE

(g) 17 Extended Spectrum Beta-Lactamase (ESBL) producers (includes community & Hospital acquired): 11 E. coli, 5 K. pneumoniae, 1 K. oxytoca (ESBL isolates are counted once per patient per year)

Created by: Layla Santiago MT(ASCP), Microbiology Supervisor & Lisa Hirt, Laboratory Resources Coordinator 08/2014

Approved by: Steven Hickerson, MD, Medical Director of Infection Prevention & Amy Beasley, RN, MSN, CPHQ, CIC, Director of Infection Prevention